NREP
NEW REPRESENTATIVE AT IB RECEIVED
15/11/2024
Voltar para busca
Dado oficial do USPTO
NERVIANO MEDICAL SCIENCES PART OF NMS GROUP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
NERVIANO MEDICAL SCIENCES PART OF NMS GROUP
ST13
US500000079326491Classe
5, 41, 42
Pedido
79326491
Registro
6993809
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
15/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 41, 42
Data de depósito
09/07/2021
Data de registro
07/03/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/03/2023
Última transação
07/03/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
IT
Examinador
STURMAN, MELISSA
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NERVIANO MEDICAL SCIENCES S.R.L.
Representantes
Jeffrey B. Sladkus, Esq. The Sladkus Law Group
Classificação técnica
Classes Nice
Classe 5Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparations for treating cancermyocardium infarction and malaria; sanitary preparations for medical purposes; biological preparations for medical purposes for the treatment of cancermyocardium infarction and malaria; chemical preparations for pharmaceutical purposesfor the treatment of cancermyocardium infarction and malaria; chemico-pharmaceutical preparations for the treatment of cancermyocardium infarction and malaria; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of cancermyocardium infarction and malaria; pharmaceuticals in the nature of anti-cancer preparations
Classe 41
Educationproviding classescoursesseminarsworkshopsrelated to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; providing of training related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; providing entertainment in the nature of exhibitionslive showsonline non-downloadable video and non-downloadable films via video-on-demand transmission servicesrelated to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; educational servicesproviding know-how transfer training related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; providing online electronic publicationsnot downloadablein the nature of booksmagazinesnewsletters related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; publication of textsother than publicity textsrelated to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; arranging and conducting of conferencescongresses and symposium related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field
Classe 42
Scientifictechnologicalanalysis and research servicesscientific research and development in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; biological research in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; chemical research in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; medical and scientific researchconducting clinical trials for others in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; quality control for others in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/07/2023
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
11/06/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
11/06/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/06/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/03/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
07/03/2023
GPNX
NOTIFICATION PROCESSED BY IB
21/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/12/2022
PUBO
PUBLISHED FOR OPPOSITION
20/12/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
30/11/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
30/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/09/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/09/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/09/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/09/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/09/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
12/09/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/09/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/09/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/09/2022
RFNT
REFUSAL PROCESSED BY IB
22/06/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/06/2022
RFRR
REFUSAL PROCESSED BY MPU
02/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/06/2022
CNRT
NON-FINAL ACTION WRITTEN
01/06/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
23/05/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/04/2022
CNRT
NON-FINAL ACTION WRITTEN
12/04/2022
DOCK
ASSIGNED TO EXAMINER
29/03/2022
MAFR
APPLICATION FILING RECEIPT MAILED
30/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NERVIANO MEDICAL SCIENCES PART OF NMS GROUP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.